Your browser is no longer supported. Please, upgrade your browser.
Purple Biotech Ltd.
Index- P/E- EPS (ttm)- Insider Own1.88% Shs Outstand17.51M Perf Week-4.67%
Market Cap67.94M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float16.24M Perf Month-4.43%
Income- PEG- EPS next Q- Inst Own24.90% Short Float1.88% Perf Quarter-37.12%
Sales1.00M P/S67.94 EPS this Y- Inst Trans- Short Ratio0.70 Perf Half Y-5.13%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-20.59%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.60 - 14.40 Perf YTD1.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.68% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low5.28% ATR0.22
Employees13 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)37.16 Volatility4.07% 5.66%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close3.88
ShortableYes LT Debt/Eq- EarningsMar 02 BMO Payout- Avg Volume434.01K Price3.79
Recom- SMA20-9.33% SMA50-11.64% SMA200-18.44% Volume140,000 Change-2.32%
Apr-23-21 08:00AM  
Apr-13-21 08:17AM  
Mar-19-21 08:00AM  
Mar-11-21 08:02AM  
Mar-03-21 07:00AM  
Mar-02-21 07:00AM  
Jan-18-21 07:41AM  
Jan-04-21 09:40AM  
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.